LONDON--(BUSINESS WIRE)--The overactive bladder therapeutics market is poised to grow by USD 311.17 million during 2020-2024 progressing at a CAGR of almost 2% during the forecast period.
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis
The report on the overactive bladder therapeutics market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by the increasing number of drug approvals.
The overactive bladder therapeutics market analysis includes the product segment and geography landscape. This study identifies the advent of combination therapy as one of the prime reasons driving the overactive bladder therapeutics market growth during the next few years.
This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
The overactive bladder therapeutics market covers the following areas:
Overactive Bladder Therapeutics Market Sizing
Overactive Bladder Therapeutics Market Forecast
Overactive Bladder Therapeutics Market Analysis
Companies Mentioned
- AbbVie Inc.
- Astellas Pharma Inc.
- Endo International Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Mylan NV
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product
- Anticholinergics - Market size and forecast 2019-2024
- Beta-3 adrenergic agonists - Market size and forecast 2019-2024
- Other OAB therapeutics - Market size and forecast 2019-2024
- Market opportunity by Product
Customer Landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Volume drivers – Demand led growth
- Volume drivers – External factors
- Market challenges
- Market trends
Vendor Landscape
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AbbVie Inc.
- Astellas Pharma Inc.
- Endo International Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Mylan NV
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
